FAAH Pharma's Unattributed VC Round

FAAH Pharma raised a round of funding on August 11, 2014. Investors include TVM Capital Life Science.

FAAH Pharma is a project-focused company developing a clinical asset initially for postherpetic neuralgia. The compound is an inhibitor of fatty acid amide hydrolase or "FAAH." The asset has been test…

Articles about FAAH Pharma's Unattributed VC Round: